ATI Inc. (ATI) is rated Buy, driven by accelerating growth and margin expansion from the ongoing air travel industry recovery. Aerospace & defense, especially partnerships with Boeing and Airbus, now
DALLAS , Sept. 30, 2025 /PRNewswire/ -- ATI (NYSE: ATI) has scheduled the live webcast for its third quarter 2025 earnings conference call on Tuesday, October 28, 2025, at 7:30 a.m.
ATI (ATI) closed at $79.26 in the latest trading session, marking a -4.29% move from the prior day.
TORONTO, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Altai Resources Inc. (TSXV: ATI) (“Altai” or the “Company”) announced today that it has sold its ownership of a 50% working interest in the oil well
'NeedleCert PrivilegePath' drives exceptional learner adoption and clinical consistency DOWNERS GROVE, Ill. , Sept. 25, 2025 /PRNewswire/ -- ATI Physical Therapy, a nationally recognized provider of o

Here's Why ATI (ATI) is a Strong Momentum Stock

10:50am, Thursday, 25'th Sep 2025
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often
ATI (ATI) closed at $79.87 in the latest trading session, marking a -1.07% move from the prior day.
In the latest trading session, ATI (ATI) closed at $79.47, marking a +2.61% move from the previous day.
ATI (ATI) closed the most recent trading day at $76.39, moving +2.02% from the previous trading session.
Appointments of experienced leaders strengthen ATI's position as aerospace and defense leader DALLAS , Sept. 10, 2025 /PRNewswire/ -- ATI Inc. (NYSE: ATI) today announced the appointment of two proven
Search for successor underway DALLAS , Sept. 10, 2025 /PRNewswire/ -- ATI Inc. (NYSE: ATI) today announced that Executive Vice President - Finance and Chief Financial Officer Don Newman has informed t
Appili Non-Clinical Director to join NATO and allied representatives and present ATI-1701 biodefense vaccine as a potential solution to the tularemia threat Appili Non-Clinical Director to join NATO a
- Late Breaking Abstract to Present Additional Data from Aclaris' Phase 2a Trial of ATI-2138 in Atopic Dermatitis- WAYNE, Pa., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: AC
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE